Dupilumab for Atopic Dermatitis Linked to Increased Risk of Psoriasis

Dupilumab for Atopic Dermatitis Linked to Increased Risk of Psoriasis

(MedPage Today) -- The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents, according to a retrospective cohort study. Among over 19,000 matched...

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis

The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis.

Dupilumab-Treated Patients with Atopic Dermatitis at Increased Risk of Psoriasis

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.